Clinical Trial Update: A Phase IIa Study of Vitamin D3 Tolerogenic Dendritic Cells (tolDC) for Multiple Sclerosis [Phase 2]

View source ↗

Summary

A Phase IIa clinical trial evaluating Vitamin D3 tolerogenic dendritic cells for multiple sclerosis; the study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Vitamin D3 tolerogenic dendritic cells (tolDC)

Snippet

Sponsor: University Hospital, Antwerp | Conditions: Multiple Sclerosis | Phase 2 | Status: NOT_YET_RECRUITING